sanofi - Search News

News

Sanofi buys Vigil Neuroscience for $470m

Seeking Alpha on MSN · 2d

Sanofi to buy Vigil Neuroscience in $470M deal (update)

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) for $470M in cash, potentially reaching $600M with milestone payments. Following a trading halt,

Investopedia on MSN · 1d

Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

Key Takeaways Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi.French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing,

The Wall Street Journal on MSN · 2d

Sanofi to Buy Vigil Neuroscience for About $470 Million

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company’s pipeline.

Medical Dialogues13m

Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to ...

Fierce Biotech2d

Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi’s $130M Morristown flagship puts people first

Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.

New Jersey Business Magazine22h

Sanofi Opens $130M Offices in Morristown

Global healthcare company Sanofi yesterday formally opened its new flagship US offices at M Station West in Morristown.

1don MSN

US Approves GSK Lung Disease Drug, Fueling Sanofi Rivalry

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

GSK Wins COPD Expansion for Nucala After FDA Delay

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results